Preferred Label : iloprost;
MeSH definition : An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism.
It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than
the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation
and inhibits platelet aggregation.;
MeSH synonym : ciloprost;
CISMeF synonym : CoTherix brand of iloprost;
MeSH hyponym : ventavis; ZK-36374; ZK 36374; ZK36374;
MeSH CAS label : pentanoic acid, 5-(hexahydro-5-hydroxy-4-(3-hydroxy-4-methyl-1-octen-6-ynyl)-2(1H)-pentalenylidene)-;
MeSH Related Number : 78919-13-8 (Iloprost);
Registry Number MeSH : 78919-13-8;
Wikipedia link : https://en.wikipedia.org/wiki/Iloprost;
Is substance : O;
UNII : JED5K35YGL;
InChIKey : HIFJCPQKFCZDDL-ACWOEMLNSA-N;
Origin ID : D016285;
UMLS CUI : C0079594;
- ATC code(s)
- Allowable qualifiers
- Currated CISMeF NLP mapping
- Manual BTNT mappings - CISMeF
- Pharmacological action(s)
- Record concept(s)
- Related MeSH Supplementary Concept(s)
- Semantic type(s)
- UMLS correspondences (same concept)
- Validated automatic mappings to BTNT
An eicosanoid, derived from the cyclooxygenase pathway of arachidonic acid metabolism.
It is a stable and synthetic analog of EPOPROSTENOL, but with a longer half-life than
the parent compound. Its actions are similar to prostacyclin. Iloprost produces vasodilation
and inhibits platelet aggregation.
https://www.has-sante.fr/jcms/p_3146602/fr/iloprost-teva
2020
false
false
false
France
infusions, intravenous
drugs, generic
evaluation of the transparency committee
iloprost
---
https://www.has-sante.fr/jcms/p_3135580/fr/ilomedine
2019
false
false
false
France
French
iloprost
treatment outcome
insurance, health, reimbursement
infusions, intravenous
raynaud disease
iloprost
ischemia
lower extremity
chronic disease
vasodilator agents
evaluation of the transparency committee
---
http://www.has-sante.fr/portail/jcms/c_2013186/fr/ventavis
2015
true
France
French
insurance, health, reimbursement
administration, inhalation
hypertension, pulmonary
vasodilator agents
iloprost
treatment outcome
evaluation of the transparency committee
---
https://www.ema.europa.eu/medicines/human/EPAR/Ventavis
2012
United Kingdom
French
English
syndication feed
hypertension, pulmonary
vasodilator agents
iloprost
treatment outcome
drug evaluation
orphan drug production
iloprost
package leaflet
drug evaluation
summary of product characteristics
---
http://www.has-sante.fr/portail/upload/docs/application/pdf/2011-05/synthese_davis_reevaluation_htap_2011-05-12_12-18-35_386.pdf
http://www.has-sante.fr/portail/jcms/c_1053751/medicaments-de-lhypertension-arterielle-pulmonaire-idiopathique-ou-associee-a-une-connectivite
2011
false
France
French
evaluation of the transparency committee
guidelines for drug use
Sildenafil Citrate
Tadalafil
hypertension, pulmonary
collagen diseases
epoprostenol
antihypertensive agents
sulfonamides
treprostinil
epoprostenol
phosphodiesterase 5 inhibitors
iloprost
receptors, endothelin
ambrisentan
phenylpropionates
DERMATITIS
survival analysis
Antihypertensives for pulmonary arterial hypertension
treatment outcome
pyridazines
Bosentan
---
http://www.has-sante.fr/portail/jcms/c_1024129/ventavis
http://www.has-sante.fr/portail/jcms/c_1024280/ventavis-ct-6292
2011
France
French
administration, inhalation
hypertension, pulmonary
vasodilator agents
iloprost
treatment outcome
orphan drug production
evaluation of the transparency committee
---
http://www.cochrane.org/fr/CD000953
2009
false
true
false
United Kingdom
France
treatment outcome
review of literature
french abstract
scleroderma, systemic
iloprost
raynaud disease
---
http://www.has-sante.fr/portail/display.jsp?id=c_245037
2005
France
French
iloprost
vasodilator agents
hypertension, pulmonary
orphan drug production
administration, inhalation
evaluation of the transparency committee
---